scholarly journals Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Nutrients ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 2887 ◽  
Author(s):  
Joo Hyun Oh ◽  
Yeon Sil Jang ◽  
Danbee Kang ◽  
Dong Kyung Chang ◽  
Yang Won Min
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Gastrointestinal Disorder ◽  
New Combination ◽  
Double Blind ◽  
Vas Score ◽  
Abdominal Symptoms ◽  
Significant Difference ◽  
Placebo Capsule ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a common and chronic gastrointestinal disorder. Probiotics may have the potential to impact the management of IBS; however, the results of trials are conflicting. This study aimed to investigate whether a mixture of lactobacilli probiotics could improve abdominal symptoms in patients with unconstipated IBS. Fifty Vietnamese patients with unconstipated IBS were randomly assigned to either the probiotics or placebo groups. During the intervention, participants took the probiotic supplement, named Foodis Lactobacillus, or placebo capsule once a day. Patients recorded their subject global assessment (SGA) weekly and were assessed with the visual analogue scale (VAS) during the 4-week study period. Patients with SGA score of 2 points or more or a decrease of more than 30% in VAS score were considered responders. Patients who responded weekly for more than 2 of the 4 weeks were considered overall responders. There was no significant difference in demographic characteristics between the groups. Overall responder rates of improvement of global IBS symptoms assessed by SGA score were significantly higher in the probiotics group (80.8%) than in the placebo group (45.8%) (p = 0.009). The overall responder rates assessed by VAS score were also higher in the probiotics group (69.2%, 41.7%, p = 0.048). There were no adverse events in either group during the study period. Our findings suggest that the new combination of Lactobacilli appears to be promising in the relief of abdominal symptoms in Vietnamese patients with unconstipated IBS.

scholarly journals Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Liang Zheng ◽  
Weimin Lu ◽  
Qi Xiao ◽  
Yaoliang Lai ◽  
Heng Fan ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Cost Effective ◽  
Gastrointestinal Disorder ◽  
Post Treatment ◽  
Therapeutic Effects ◽  
Double Blind Study ◽  
Double Blind ◽  
Pain Frequency ◽  
Irritable Bowel

AbstractIrritable bowel syndrome (IBS) is the most common gastrointestinal disorder significantly decreasing patients’ lives of quality and placing huge economic burden on our society. Existing studies indicated that the therapeutic effects maintained for a period of time after the treatments were discontinued. It is clinically important to assess these post-treatment therapeutic effects (PTTE), which prevent IBS from relapsing. To assess the PTTE in pinaverium treatment and obtain high-quality evidence to justify the use of PTTE for long-term IBS management, we performed this controlled, double blind study on patients with IBS who were randomized to pinaverium 50 mg (n = 132) or placebo (n = 132), three times daily, for 4 weeks, and were followed up for 57 weeks after the treatments. The primary endpoints were abdominal pain and stool consistency. The secondary endpoints were pain frequency and stool frequency. The tertiary endpoints were global overall symptom and adverse events. Three days after pinaverium was discontinued, endpoints rebounded only 23.2–42.8% (P < 0.015 cf. placebo). The PTTE (P < 0.05 cf. placebo) lasted 9–17 weeks, which is similar to other antispasmodics with a 15-week treatment in striking contrast to ≥ 1 year PTTE in cognitive behavior therapy and < 1 week PTTE in serotonin antagonist treatment indicating that PTTE length markedly depends on the medication class used for the treatment and less depends on treatment length. After 17 weeks, the stage could be considered as an IBS natural history [no significant differences between pinaverium and placebo (all endpoints’ P’s > 0.05)], during which an average of 51.5–56.4% of patients (pool pinaverium and placebo data together) had IBS symptoms. These results provide clinical insights into efficient and cost-effective management of refractory IBS, and lend support to the IBS management that the selection of a therapy should consider both its effectiveness during treatment and its PTTE after the treatment.Trial registration number: NCT02330029 (16/08/2016).

scholarly journals Effect of Mentha aquatica L. Extract on Bloating Symptom of Irritable Bowel Syndrome Disease: A Double-Blind Randomized, Placebo-Controlled Study

2022 ◽  
Author(s):  
Farzaneh Assadollah pour ◽  
Assie Jokar ◽  
Mohammad Azadbakht ◽  
Ebrahim Nasiri ◽  
Zohreh Bari ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Controlled Trial ◽  
Gastrointestinal Disorder ◽  
Controlled Study ◽  
Bowel Habit ◽  
Double Blind ◽  
Mentha Aquatica ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that causes abdominal pain, distension, change of bowel habit, bloating, constipation, diarrhea, and mucus discharge along with stools. Although the disease causes long-term and agonizing pain, no ideal cure has been found for it so far. This study aimed to investigate the efficacy and compliance of Mentha aquatica L. extract for the treatment of bloating caused by IBS. This double-blind, randomized, placebo-controlled trial study was conducted in Tooba gastroenterology clinic in Sari, Iran, during 2019 (from January to May). A total of 104 patients with IBS in the age range of 20-80 years were randomly divided into two parallel groups of herbal medicine (MAC-330) and placebo. Study period consisted of a 4 weeks of administration, and 2 weeks of follow-up. IBS-associated symptoms including severity of bloating (as primary outcome) and frequency of defecation and abdominal pain were evaluated using a questionnaire before treatment, 1, 2 and 4 weeks after beginning treatment and 2 weeks after stopping treatment. There were no significant differences between the two groups in terms of their baseline characteristics (p > 0.05). The severity of bloating was significantly reduced in the both groups at fourth week (p < 0.030) and 2 weeks after stopping intervention (sixth week) (p < 0.026). The frequency of defecation has increased with the onset of the intervention until the fourth week of the treatment which was not significant. The abdominal pain reduced during the 4 weeks’ intervention, but it was not significant. Based on the obtained results, MAC-330 could not be used as an effective treatment for patients with IBS in short time; however, it reduces the abdominal bloating and pain in these patients, especially in the long-term use.

scholarly journals The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial

2020 ◽  
Vol 26 (1) ◽  
pp. 117-127 ◽  
Author(s):  
Seung Yong Shin ◽  
Bong Ki Cha ◽  
Won-Seok Kim ◽  
Jae Yong Park ◽  
Jeong Wook Kim ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Irritable Bowel

No benefit of faecal microbiota transplantation for IBS-D

2020 ◽  
Vol 58 (6) ◽  
pp. 87-87
Keyword(s):  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Faecal Microbiota ◽  
Double Blind ◽  
Faecal Microbiota Transplantation ◽  
Irritable Bowel

AbstractReview of: Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2019;4:675–85.

Sign in / Sign up

Export Citation Format

Share Document